Form 8-K - Current report:
SEC Accession No. 0001999371-25-004974
Filing Date
2025-04-29
Accepted
2025-04-29 16:08:13
Documents
16
Period of Report
2025-04-29
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_042925.htm   iXBRL 8-K 30592
2 PRESS RELEASE OF THE COMPANY, APRIL 29, 2025 ex99-01.htm EX-99.01 30467
3 TFF2-MEDIATED CXCR4 PARTIAL AGONISM OUTPERFORMS CXCR4 ANTAGONISM ex99-02.htm EX-99.02 9354
7 GRAPHIC ex99-02_img01.jpg GRAPHIC 810333
  Complete submission text file 0001999371-25-004974.txt   1377471

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnxp-20250429.xsd EX-101.SCH 3023
5 XBRL LABEL FILE tnxp-20250429_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE tnxp-20250429_pre.xml EX-101.PRE 24170
18 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_042925_htm.xml XML 3549
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 25887437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)